CKS1B promotes the growth of ovarian cancer cells by regulating the expression of PD-L1

Ovarian cancer has high rates of morbidity and mortality and a poor prognosis. A growing body of research suggests that CDC28 protein kinase regulatory subunit 1B (CKS1B) influences the progression of numerous carcinomas. However, the specific mechanism of CKS1B in ovarian cancer has yet to be elucidated. Here, this study aimed to investigate the involvement of CKS1B in the progression of ovarian cancer. Initially, we collected data from the Cancer Genome Atlas (TCGA) website and ovarian cancer tissues showed elevated CKS1B expression compared to healthy tissues, indicating a poorer prognosis. Immunohistochemistry (IHC) was used to detect CKS1B and programmed cell death 1-ligand 1 (PD-L1) levels and demonstrated that CKS1B is positively related to PD-L1 expression. Then, short-interfering (si)-CKS1B or si-negative control (si-NC) constructs were transfected into SKOV3 and OVCAR3 cells. Subsequently, cell viability was measured by cell counting kit-8 (CCK8) and colony formation assays, and the extent of apoptosis was assessed using flow cytometry. We found that CKS1B silencing inhibited cell growth and promoted cell apoptosis in ovarian cancer. In addition, the expression levels of CKS1B, B-cell lymphoma-2 (BCL2)-associated X (Bax), cleaved-caspase3 and PD-L1 were determined by western blotting. Furthermore, to investigate whether the inhibitory effects of si-CKS1B on ovarian cancer is related to the levels of PD-L1, we added PD-L1 to si-CKS1B transfected cells and found that cells that had been supplemented with PD-L1 exhibited an increased cell growth rate and a reduced apoptosis rate than si-CKS1B cells. Collectively, our data we demonstrated high levels of CKS1B in ovarian cancer cells, and found that the knockdown of CKS1B could alleviate the development of ovarian tumors by dysregulating the level of PD-L1 expression.

CKS1B; PD-L1; Ovarian cancer; Proliferation

[1] van Wagensveld L, Sonke GS, Van de Vijver KK, Horlings HM, Kruitwagen RFPM, van der Aa MA. Characteristics of long-term survival in advanced stage ovarian cancer: a nationwide cohort in the Netherlands. European Journal of Gynaecological Oncology. 2022; 43: 1–9.

[2] Chunju Xu XL. Research trends in the early diagnosis of ovarian cancer during 2001–2020: a bibliometric analysis. European Journal of Gynaecological Oncology. 2022; 43: 321–334.

[3] Taylor J, Miller J, Ballard E, Byrd C, Holloway A, Smith A, et al. Improving the mortality index among gynecologic oncology patients. European Journal of Gynaecological Oncology. 2022; 43: 111–117.

[4] Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Seminars in Oncology Nursing. 2019; 35: 151–156.

[5] Hao L, Wang J, Liu B, Yan J, Li C, Jiang J, et al. M6a-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. BBA—Molecular Cell Research. 2021; 1868: 118878.

[6] Roett MA, Evans P. Ovarian cancer: an overview. American Family Physician. 2009; 80: 609–616.

[7] Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian cancer immunotherapy and personalized medicine. International Journal of Molecular Sciences. 2021; 22: 6532.

[8] Gao C, Shi J, Zhang J, Li Y, Zhang Y. Chemerin promotes proliferation and migration of ovarian cancer cells by upregulating expression of PD-L1. Journal of Zhejiang University Science B. 2022; 23: 164–170.

[9] Erin C Kaser, Marco Lequio, Ziwen Zhu, Zachary E Hunzeker, Aidan J. Heslin, Kyle P. D’mello, et al. Ovarian cancer immunotherapy en route: IL9 inhibits growth of ovarian cancer and upregulates its expression of Ox40L and 4-1BBL. European Journal of Gynaecological Oncology. 2022; 43: 163–168.

[10] Gao H, Zhang J, Ren X. PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling. Bioscience Reports. 2019; 39: BSR20191041.

[11] Yang Y, Xia L, Wu Y, Zhou H, Chen X, Li H, et al. Programmed death ligand‐1 regulates angiogenesis and metastasis by participating in the c‐JUN/VEGFR2 signaling axis in ovarian cancer. Cancer Communications. 2021; 41: 511–527.

[12] Li L, Wang J, Zhang Z, Yang Q, Deng Z, Zou W, et al. Identification of CKS1B as a prognostic indicator and a predictive marker for immunotherapy in pancreatic cancer. Frontiers in Immunology. 2022; 13: 1052768.

[13] Wang H, Zhang Z, Yan Z, Ma S. CKS1B promotes cell proliferation and invasion by activating STAT3/PD‐L1 and phosphorylation of Akt signaling in papillary thyroid carcinoma. Journal of Clinical Laboratory Analysis. 2021; 35: e23565.

[14] Deng T, Liu Y, Yang Y, Yuan L, Liu F, Wang X, et al. Regulation of microRNA miR-197-3p/CDC28 protein kinase regulatory subunit 1B (CKS1B) axis by Circular RNA hsa_circ_0000285 promotes glioma progression. Bioengineered. 2022; 13: 4757–4772.

[15] Li N, Lin P, Zuo Z, You MJ, Shuai W, Orlowski R, et al. Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis. Cancer Medicine. 2023; 12: 14293–14304.

[16] Liu X, Zhao D. CKS1B promotes the progression of hepatocellular carcinoma by activating JAK/STAT3 signal pathway. Animal Cells and Systems. 2021; 25: 227–234.

[17] Wang K, Zhang M, Wang J, Sun P, Luo J, Jin H, et al. A systematic analysis identifies key regulators involved in cell proliferation and potential drugs for the treatment of human lung adenocarcinoma. Frontiers in Oncology. 2021; 11: 737152.

[18] Zhu J, Yan L, Wang Q. Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis. Journal of Ovarian Research. 2021; 14: 112.

[19] Wan C, Keany MP, Dong H, Al-Alem LF, Pandya UM, Lazo S, et al. Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high-grade serous ovarian cancer. Cancer Research. 2021; 81: 158–173.

[20] Fujita Y, Yagishita S, Hagiwara K, Yoshioka Y, Kosaka N, Takeshita F, et al. The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Molecular Therapy. 2015; 23: 717–727.